日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Safety and efficacy of HH2853, a novel EZH1/2 dual inhibitor, in patients with refractory solid tumours or non-Hodgkin lymphomas: a phase I study

新型 EZH1/2 双重抑制剂 HH2853 在难治性实体瘤或非霍奇金淋巴瘤患者中的安全性和有效性：一项 I 期研究

期刊:EClinicalMedicine
影响因子:10
doi:10.1016/j.eclinm.2025.103398
Fan, Zhengfu; Wang, Jin; Liu, Dan; Shen, Lin; Fang, Meiyu; Johnson, Patrick; Tun, Han; Sommerhalder, David; Yang, Jilong; Yang, Yun; Munozi, Javier; Zhu, Jun; Gao, Tian; Li, Zhiming; Li, Xian'an; Ma, Qiuying; Lv, Chao; Yu, Songda; Li, Fugen; Song, Yuqin; Gong, Jifang
淋巴瘤
EZH1
发表日期：2025
文献求助 收藏

A Phase 3 Study of the Efficacy and Safety of Pexidartinib in East Asian Patients with Tenosynovial Giant Cell Tumor

一项评估佩西达替尼治疗东亚腱鞘巨细胞瘤患者疗效和安全性的3期研究

期刊:Oncology and Therapy
影响因子:3.2
doi:10.1007/s40487-025-00365-z
Xu, Hairong; Wu, Po-Kuei; Ye, Zhaoming; Fan, Zhengfu; Li, Tao; Chen, Tom Wei-Wu; Shen, Jingnan; Yan, Wangjun; Achiwa, Issei; Yoh, Kazukoh; Kikumori, Kunika; Hiruma, Yoshiharu; Greenberg, Jonathan; Niu, Xiaohui
细胞生物学
发表日期：2025
文献求助 收藏

Efficacy and safety of JMT103 in patients with unresectable or surgically-challenging giant cell tumor of bone: a multicenter, phase Ib/II study

JMT103治疗不可切除或手术难度大的骨巨细胞瘤患者的疗效和安全性：一项多中心Ib/II期研究

期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-024-53686-4
Xu, Hairong; Zhou, Yong; Liang, Li; Shen, Jingnan; Yan, Wangjun; Wang, Jin; Li, Jianmin; Zhang, Xiaojing; Huang, Gang; Bi, Wenzhi; Guo, Zheng; Xiao, Yanbin; Lin, Jianhua; Yao, Weitao; Tong, Zhichao; Zhou, Wenxian; Zhang, Guochuan; Ye, Zhaoming; Wang, Dong; Yang, Jilong; Fan, Zhengfu; Liu, Caigang; Qu, Guofan; Zhang, Qing; Wei, Feng; Liu, Weifeng; Tu, Chongqi; Li, Hong; Yuan, Jing; Niu, Xiaohui
细胞生物学
发表日期：2024
文献求助 收藏

Knockdown of PRDX2 Inhibits the Proliferation, Growth, Migration, Invasion, and MMP9 Activity of Ewing's Sarcoma Cells Cultured In Vitro.

敲除 PRDX2 可抑制体外培养的尤文氏肉瘤细胞的增殖、生长、迁移、侵袭和 MMP9 活性

期刊:Cancer Reports
影响因子:1.9
doi:10.1002/cnr2.2122
Xue Ruifeng, Fan Zhengfu, An Yunhe
细胞生物学
发表日期：2024
文献求助 收藏

Phase II Study of TQB2450, a Novel PD-L1 Antibody, in Combination with Anlotinib in Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma

TQB2450（一种新型PD-L1抗体）联合安罗替尼治疗局部晚期或转移性软组织肉瘤患者的II期研究

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-22-0871
Liu, Jiayong; Gao, Tian; Tan, Zhichao; Li, Shu; Xu, Jie; Bai, Chujie; Xue, Ruifeng; Xie, Lu; Zhang, Lu; Fan, Zhengfu; Guo, Wei
PD-L1
发表日期：2022
文献求助 收藏

Clinical features and therapeutic outcomes of alveolar soft part sarcoma in children: A single-center, retrospective study

儿童肺泡软组织肉瘤的临床特征和治疗结果：一项单中心回顾性研究

期刊:Frontiers in Oncology
影响因子:3.3
doi:10.3389/fonc.2022.1019911
Tan, Zhichao; Liu, Jiayong; Xue, Ruifeng; Fan, Zhengfu; Bai, Chujie; Li, Shu; Gao, Tian; Zhang, Lu; Wang, Xinyu
发表日期：2022
文献求助 收藏

Anlotinib for Recurrent or Metastatic Primary Malignant Bone Tumor: A Multicenter, Single-Arm Trial

安罗替尼治疗复发性或转移性原发性恶性骨肿瘤：一项多中心、单臂试验

期刊:Frontiers in Oncology
影响因子:3.3
doi:10.3389/fonc.2022.811687
Tang, Lina; Niu, Xiaohui; Wang, Zhen; Cai, Qiqing; Tu, Chongqi; Fan, Zhengfu; Yao, Yang
肿瘤
肿瘤免疫
发表日期：2022
文献求助 收藏

A novel TMTC2-NTRK3 fusion in undifferentiated high-grade pleomorphic sarcoma

未分化高级别多形性肉瘤中一种新型的TMTC2-NTRK3融合

期刊:Journal of Cancer Research and Clinical Oncology
影响因子:2.8
doi:10.1007/s00432-022-04249-x
Bai, Chujie; Zhang, Lu; Wang, Yaohui; You, Xia; Ju, Yongzhi; Sun, Tingting; Fan, Zhengfu
NTRK3
发表日期：2022
文献求助 收藏

The efficacy of (99m)Tc-rituximab as a tracer for sentinel lymph node biopsy in cutaneous melanoma patients

(99m)Tc-利妥昔单抗作为皮肤黑色素瘤患者前哨淋巴结活检示踪剂的疗效

期刊:Annals of Translational Medicine
影响因子:
doi:10.21037/atm-21-6890
Liu, Jiayong; Tan, Zhichao; Xue, Ruifeng; Fan, Zhengfu; Bai, Chujie; Li, Shu; Gao, Tian; Zhang, Lu; Fang, Zhiwei; Si, Lu
黑色素瘤
发表日期：2022
文献求助 收藏

Efficacy of PD-1 inhibitors combined with pegylated liposomal doxorubicin and dacarbazine compared with liposomal doxorubicin and dacarbazine in advanced leiomyosarcoma patients: a retrospective, single-institutional cohort study

PD-1抑制剂联合聚乙二醇化脂质体阿霉素和达卡巴嗪与单用脂质体阿霉素和达卡巴嗪治疗晚期平滑肌肉瘤患者的疗效比较：一项回顾性单中心队列研究

期刊:Annals of Translational Medicine
影响因子:
doi:10.21037/atm-22-3963
Tan, Zhichao; Wang, Xinyu; Liu, Jiayong; Fan, Zhengfu; Gao, Tian; Bai, Chujie; Xue, Ruifeng; Li, Shu; Zhang, Lu
PD-1
发表日期：2022
文献求助 收藏